Panacos Pharmaceuticals, Inc.
PANC · OTC
9/30/2008 | 6/30/2008 | 3/31/2008 | 12/31/2007 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.00 | 0.01 | -0.01 |
| FCF Yield | -476.89% | -323.53% | -226.77% | -169.50% |
| EV / EBITDA | 0.21 | 0.55 | 1.20 | 1.60 |
| Quality | ||||
| ROIC | 0.00% | 0.00% | 0.00% | 0.00% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.96 | 0.80 | 0.99 | 0.76 |
| Growth | ||||
| Revenue 3-Year CAGR | -38.52% | -42.10% | -37.41% | -44.43% |
| Free Cash Flow Growth | -0.01% | 8.22% | -19.05% | -2.69% |
| Safety | ||||
| Net Debt / EBITDA | 0.44 | 0.82 | 1.68 | 2.07 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 378.75 | 405.00 | 308.57 | 601.36 |